Resultados de procura - Joachim Schessl

  • Mostrando 1 - 8 Resultados de 8
Limitar resultados
  1. 1
    Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (“ProDERM Study”)

    Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (“ProDERM Study”) por Rohit Aggarwal, Christina Charles‐Schoeman, Joachim Schessl, Mazen M. Dimachkie, Irene K. Beckmann, Todd Levine

    Publicado 2021
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  2. 2
    Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study

    Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study por Rohit Aggarwal, Joachim Schessl, Christina Charles‐Schoeman, Zsuzsanna Bata‐Csörgõ, Mazen M. Dimachkie, Zoltán Griger, Sergey Moiseev, Chester V. Oddis, Elena Schiopu, Jiří Vencovský, Irene K. Beckmann, Elisabeth Clodi, Todd Levine

    Publicado 2024
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    Identification of FHL1 as a regulator of skeletal muscle mass: implications for human myopathy

    Identification of FHL1 as a regulator of skeletal muscle mass: implications for human myopathy por Belinda S. Cowling, Meagan J. McGrath, Mai-Anh Nguyen, Denny L. Cottle, Anthony J. Kee, S. Brown, Joachim Schessl, Yaqun Zou, Josephine E. Joya, Carsten G. Bönnemann, Edna C. Hardeman, Christina A. Mitchell

    Publicado 2008
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial

    Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial por Maggie C. Walter, Peter Reilich, Simone Thiele, Joachim Schessl, Herbert Schreiber, Karlheinz Reiners, Wolfram Kreß, C. Müller‐Reible, Matthias Vorgerd, Péter Urbán, Bertold Schrank, Marcus Deschauer, Beate Schlotter‐Weigel, Ralf Kohnen, Hanns Lochmüller

    Publicado 2013
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    New insights into the protein aggregation pathology in myotilinopathy by combined proteomic and immunolocalization analyses

    New insights into the protein aggregation pathology in myotilinopathy by combined proteomic and immunolocalization analyses por A. Maerkens, Montse Olivé, A. Schreiner, S. Feldkirchner, Joachim Schessl, Julian Uszkoreit, Katalin Barkovits, A. Güttsches, Verena Theis, Martin Eisenacher, Martin Tegenthoff, Lev G. Goldfarb, Rolf Schröder, Benedikt Schoser, Peter F. M. van der Ven, Dieter O. Fürst, Matthias Vorgerd, Katrin Marcus, Rudolf A. Kley

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Proteomic identification of FHL1 as the protein mutated in human reducing body myopathy

    Proteomic identification of FHL1 as the protein mutated in human reducing body myopathy por Joachim Schessl, Yaqun Zou, Meagan J. McGrath, Belinda S. Cowling, Baijayanta Maiti, Steven S. Chin, C. Sewry, Roberta Battini, Ying Hu, Denny L. Cottle, Michael Rosenblatt, Lynn A. Spruce, Arupa Ganguly, Janbernd Kirschner, Alexander R. Judkins, Jeffrey A. Golden, Hans‐Hilmar Goebel, Francesco Muntoni, Kevin M. Flanigan, Christina A. Mitchell, Carsten G. Bönnemann

    Publicado 2008
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    Clinical, histological and genetic characterization of reducing body myopathy caused by mutations in FHL1

    Clinical, histological and genetic characterization of reducing body myopathy caused by mutations in FHL1 por Joachim Schessl, Ana Lía Taratuto, Caroline A. Sewry, Roberta Battini, Steven S. Chin, Baijayanta Maiti, Alberto Dubrovsky, Marcela García Erro, Graciela Espada, Monica Robertella, M. Saccoliti, Patrícia Olmos Rueda, Leslie Bridges, Peter Standring, Ying Hu, Yaqun Zou, Kathryn J. Swoboda, Mena Scavina, Hans‐Hilmar Goebel, Christina A. Mitchell, Kevin M. Flanigan, Francesco Muntoni, Carsten G. Bönnemann

    Publicado 2008
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  8. 8
    Trial of Intravenous Immune Globulin in Dermatomyositis

    Trial of Intravenous Immune Globulin in Dermatomyositis por Rohit Aggarwal, Christina Charles‐Schoeman, Joachim Schessl, Zsuzsanna Bata‐Csörgõ, Mazen M. Dimachkie, Zoltán Griger, Sergey Moiseev, Chester V. Oddis, Elena Schiopu, Jiří Vencovský, Irene K. Beckmann, Elisabeth Clodi, Olga S. Bugrova, Katalin Dankó, Floranne C. Ernste, Namita Goyal, Marvin Heuer, Marie Hudson, Yessar Hussain, Chafic Karam, Nina Magnolo, Ronald J. Nelson, Н. З. Позур, Liudmyla Nykodymivna Prystupa, Miklós Sárdy, Guillermo J. Valenzuela, Anneke J. van der Kooi, Tuan Vu, Margitta Worm, Todd Levine

    Publicado 2022
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: